Stocktoria
IDEAYA Biosciences, Inc. IDYA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-05-23
IDEAYA Biosciences, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $218.7M | $7.0M | $23.4M | $50.9M | $27.9M |
| R&D expense | $314.7M | $294.7M | $129.5M | $89.5M | $58.2M |
| Operating income | -$159.3M | -$327.0M | -$134.4M | -$62.5M | -$50.3M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$113.7M | -$274.5M | -$113.0M | -$58.7M | -$49.8M |
| EPS (diluted) | $-1.28 | $-3.36 | $-1.96 | $-1.42 | $-1.41 |
| Operating cash flow | -$71.1M | -$247.6M | -$115.2M | -$87.2M | -$55.8M |
| Free cash flow | -$73.5M | -$251.4M | -$117.6M | -$90.6M | -$58.4M |
| Cash & equivalents | $112.8M | $84.4M | $157.0M | $68.6M | $92.0M |
| Total assets | $1.1B | $1.1B | $649.3M | $388.0M | $381.3M |
| Total liabilities | $86.4M | $64.9M | $28.2M | $38.5M | $79.8M |
| Shareholders' equity | $1.0B | $1.1B | $621.1M | $349.5M | $301.5M |
Source: SEC EDGAR filings · CIK 0001676725 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.